Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

MLA

Girish Dhall, et al. “Selumetinib in Paediatric Patients with BRAF-Aberrant or Neurofibromatosis Type 1-Associated Recurrent, Refractory, or Progressive Low-Grade Glioma: A Multicentre, Phase 2 Trial.” The Lancet. Oncology, vol. 20, no. 7, Feb. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ac07fedc1b008487f15b2b5a64ead9fb&authtype=sso&custid=ns315887.

APA

Girish Dhall, Laurence Austin Doyle, Lindsay Kilburn, Soonmee Cha, Sofia Haque, Susan G. Kreissman, David S. Enterline, Ira J. Dunkel, Roger J. Packer, Jason Fangusaro, Clinton F. Stewart, Zoltan Patay, Maryam Fouladi, David T.W. Jones, Shengjie Wu, Ashok Panigrahy, Michael Fisher, Ibrahim Qaddoumi, Patricia Baxter, … Jessica S Stern. (2019). Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. The Lancet. Oncology, 20(7).

Chicago

Girish Dhall, Laurence Austin Doyle, Lindsay Kilburn, Soonmee Cha, Sofia Haque, Susan G. Kreissman, David S. Enterline, et al. 2019. “Selumetinib in Paediatric Patients with BRAF-Aberrant or Neurofibromatosis Type 1-Associated Recurrent, Refractory, or Progressive Low-Grade Glioma: A Multicentre, Phase 2 Trial.” The Lancet. Oncology 20 (7). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ac07fedc1b008487f15b2b5a64ead9fb&authtype=sso&custid=ns315887.